Evidence map›Paper›PMID 42668348›Full record

ArticleMolecular neurobiology2026

Promoting Effect of (+)-Borneol on Alzheimer's Disease Treatment in APP Transgenic Zebrafish and Its Blood-Brain Barrier Permeation Mechanism.

Zhe Han, Hongsong Chen, Yuehua Yao, Xinru Bo, Xuan Ni, Haiping Liu, Meirong Bai, Tonglaga Li, Liming Bao, Dongwei Zhang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhe HanCollege of Animal Science and Technology, Inner Mongolia Minzu University, Tongliao, 028000, Inner Mongolia, China.
Hongsong ChenCollege of Animal Science and Technology, Inner Mongolia Minzu University, Tongliao, 028000, Inner Mongolia, China.
Yuehua YaoCollege of Animal Science and Technology, Inner Mongolia Minzu University, Tongliao, 028000, Inner Mongolia, China.
Xinru BoCollege of Animal Science and Technology, Inner Mongolia Minzu University, Tongliao, 028000, Inner Mongolia, China.
Xuan NiCollege of Animal Science and Technology, Inner Mongolia Minzu University, Tongliao, 028000, Inner Mongolia, China.
Haiping LiuCollege of Life Science and Food Engineering, Inner Mongolia Minzu University, Tongliao, 028000, Inner Mongolia, China.
Meirong BaiCollege of Mongolian Medicine, Inner Mongolia Minzu University, Tongliao, 028000, Inner Mongolia, China.
Tonglaga LiCollege of Animal Science and Technology, Inner Mongolia Minzu University, Tongliao, 028000, Inner Mongolia, China.
Liming BaoCollege of Mongolian Medicine, Inner Mongolia Minzu University, Tongliao, 028000, Inner Mongolia, China.
Dongwei ZhangAffiliated Hospital of Inner Mongolia Minzu University, Tongliao, 028000, Inner Mongolia, China.
Wu DongCollege of Animal Science and Technology, Inner Mongolia Minzu University, Tongliao, 028000, Inner Mongolia, China. dongwu@imun.edu.cn.ORCID https://orcid.org/0000-0002-2372-2415

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

( +)-Borneol (Bor) has been shown to enhance drug penetration across the blood-brain barrier (BBB); yet its mechanisms of action and adjuvant effects on Alzheimer's disease (AD) drugs remain insufficiently investigated. This study systematically explored the adjuvant effects of Bor and its underlying mechanisms by employing AB wild-type zebrafish and APP transgenic zebrafish models. Results demonstrated that Bor at concentrations of 0.05 mM or lower exhibited no toxicity toward AB wild-type zebrafish, whereas 0.01 and 0.05 mM Bor significantly increased the expression of green fluorescent protein (GFP) in the zebrafish brain. Genetic analyses revealed that Bor downregulated genes encoding tight junction proteins and P-glycoprotein (P-gp). Drug treatment experiments showed that Bor enhanced the efficacy of AD therapeutic agents, including Zhenbaopill (ZBP, a traditional medicinal preparation) and the synthetic drug 8e. Specifically, Bor ameliorated AD-related behavioral impairments, inhibited cerebral apoptosis, restored the expression of AD-associated genes, normalized the activities of acetylcholine (ACh)-related enzymes, and downregulated both the mRNA and protein levels of Claudin 5. In summary, Bor enhances BBB permeability by regulating the expression of genes encoding BBB-related proteins, thereby increasing the brain concentration and bioavailability of AD drugs with anticholinesterase activity. An appropriate dose of Bor may thus contribute to enhancing the therapeutic efficacy of AD drugs.

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorBlood-Brain BarrierCamphanesAnimalsAnimals, Genetically ModifiedBrainZebrafishAmyloid beta-Protein PrecursorCamphanes8eAlzheimer’s disease (AD)APP transgenic zebrafishBlood-brain barrier (BBB)(+)-BorneolZhenbaopill (ZBP)

Identifiers

PMID42668348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.